Postural orthostatic tachycardia syndrome and crth2
AssigneeAmerimmune LLC
InventorOral ALPAN
Life of this patent
Estimating the term…
Abstract
T cell surface marker, CRTH2, is a target for treating Postural Orthostatic Tachycardia Syndrome, a hemodynamic abnormality. Targeting CRTH2 permits control of disease symptoms in POTS, for which no FDA approved treatment is currently available. Cell surface expression on certain T cell subsets characterizes the syndrome. Cell surface expression can be conveniently determined in plasma samples using flow cytometry.
Claims20
-38. (canceled)
A method of treating Postural Orthostatic Tachycardia Syndrome (POTS) in a patient, comprising:
- testing a sample of the patient for cells that express on their surfaces prostaglandin D2 receptor 2 (CRTH2), wherein the cells are one or both of memory CD4+ T cells and memory CD8+ T cells;
- comparing an amount of cells that express on their surfaces CRTH2 in the sample of the patient to an amount of cells that express on their surfaces CRTH2 in one or more healthy controls;
- identifying the patient as having a sample with significantly more cells expressing CRTH2 on their surfaces than in the healthy controls;
- and
- administering to the patient an antagonist of CRTH2.
A method of treating Postural Orthostatic Tachycardia Syndrome (POTS) in a patient, comprising:
- determining that the patient has a maximum heart rate gap greater than or equal to 30 beats per minute;
- and
- administering to the patient an antagonist of CRTH2.
A method of treating Postural Orthostatic Tachycardia Syndrome (POTS) in a patient, comprising:
- administering to a POTS patient an antagonist of CRTH2,
- wherein the POTS patient expresses significantly more prostaglandin D2 receptor 2 (CRTH2) on the surfaces of a population of its cells than is expressed in the population of cells of a group of healthy controls.
A method of treating Postural Orthostatic Tachycardia Syndrome (POTS) in a patient, comprising:
- administering an antagonist of CRTH2 to a patient that has significantly more cells expressing prostaglandin D2 receptor 2 (CRTH2) on their surfaces than one or more healthy control individuals have,
- wherein the cells comprise one or both of memory CD4+ T cells and memory CD8+ T cells.
Dependencies are inferred from the claim text.